Find disease awareness content and relevant supporting materials

Prior data about the influence of age at diagnosis of breast cancer on patient outcomes and survival has been conflicting. Using the Breast Cancer Outcomes Unit database at BC Cancer, this retrospective population-based study identified a cohort of 24,469 patients diagnosed with invasive breast cancer between 2005 and 2014

This is the second half of a two-part document updating the standard of care recommendations for spinal muscular atrophy published in 2007. This part includes updated recommendations on pulmonary management and acute care...

Roche, the Breast International Group (BIG), Breast European Adjuvant Study Team (BrEAST) and Frontier Science Foundation (FS) announced at ASCO...

Background: Adjuvant radiotherapy is prescribed after breast-conserving surgery to reduce the risk of local recurrence. However, radiotherapy is inconvenient, costly, and associated with both short-term and long-term side effects.

The FDA on 30 September 2013, granted accelerated approval to Perjeta (pertuzumab) from Genentech/Roche as part of a complete treatment...

Talazoparib has demonstrated efficacy in patients with BRCA-positive metastatic breast cancer. This study evaluated the pathologic response of talazoparib alone for 6 months in patients with a known germline BRCA...

Roche announced that the European Commission (EC) has approved Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy (the Perjeta-based...

The EU has approved the use of Perjeta (pertuzumab), from Roche, in combination with Herceptin (trastuzumab) and chemotherapy for the...

Roche announced that the European Commission has approved Kadcyla (trastuzumab emtansine) for the adjuvant (after surgery) treatment of adult patients...

Investigation use of Abraxane (paclitaxel albumin-bound particles for injectable suspension) to paclitaxel in early high-risk breast cancer patients.